Industry news · event 2025-02-21 · 3 min read
FDA Declares Semaglutide Shortage Resolved — the Legal Clock Starts on Mass Compounding (Feb 2025)
In February 2025 the FDA removed semaglutide from the drug-shortage list, starting the countdown that ended broad compounding: 503A pharmacies had until spring, 503B facilities weeks longer.
GRGLP1ProviderCompare Research Team
Pricing & policy research
Quick answerIn February 2025 the FDA removed semaglutide from the drug-shortage list, starting the countdown that ended broad compounding: 503A pharmacies had until spring, 503B facilities weeks longer.
The FDA's February 2025 determination that the semaglutide shortage was resolved was the semicolon in the sentence that began with tirzepatide's delisting the previous fall — and it started the enforcement clock on the largest compounded-drug market in U.S. history.
The mechanics mattered more than the headline. Shortage status is what makes "essentially a copy" compounding lawful at scale; remove it, and Section 503A pharmacies and 503B outsourcing facilities revert to their narrow default rules. The agency set staggered grace periods — traditional 503A pharmacies first, large 503B facilities by spring — after which mass-produced semaglutide copies would be enforcement targets rather than gray-area products.
The market reaction defined 2025: some telehealth programs announced wind-downs, others pivoted to "personalized" dosing theories under 503A, and litigation from the compounding industry sought (unsuccessfully) to reverse the underlying determination. Prices did not immediately move — the $133–$299 compounded band we track today formed under exactly this contested regime.
Why it still matters in August 2026: every compounded semaglutide purchase since spring 2025 has occurred in the narrower patient-specific lane, which is why our reviews weight pharmacy disclosure so heavily and why the legal-status guide is dated the way it is.